ArticleCureus2026
Maintained Symptom Control Following a Shortage-Driven Switch to Immediate-Release Dextroamphetamine: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ADHD is a neurodevelopmental condition marked by persistent symptoms of inattention, hyperactivity, and impulsivity. The gold standard pharmacotherapy for the treatment of ADHD is CNS psychostimulants. However, a shortage of CNS psychostimulants used for the treatment of ADHD has persisted since 2022, and many patients have been forced to switch medications or have been unable to obtain medication at all, raising concerns about symptom management and quality of life. This case report describes a 30-year-old female who was unable to obtain lisdexamfetamine amid the shortage, found mixed amphetamine salts ineffective, but found success with immediate-release dextroamphetamine sulfate, a less frequently used amphetamine. This report serves to demonstrate that immediate-release dextroamphetamine sulfate may be a viable alternative stimulant to address the shortage; however, more research must be conducted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.